Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in Advanced Neuroendocrine Cancers
NCT02318784Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2015
- Primary completion
- May 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in neuroendocrine cancer, sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate. Started Jul 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
neuroendocrine cancer
Beyond the preview
Go deeper on NCT02318784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318784.